G9a in Cancer: Mechanisms, Therapeutic Advancements, and Clinical Implications
department or school: Medicine, Faculty of
department or school: Other UBC
department or school: Urologic Sciences, Department of
data provider: DSpace
identifier citation: Cancers 16 (12): 2175 (2024)
contributor: Vancouver Prostate Centre
contributor: BC Cancer Research Centre. Department of Experimental Therapeutics
creator: Ni, Yuchao
creator: Shi, Mingchen
creator: Liu, Liangliang
creator: Lin, Dong
creator: Zeng, Hao
creator: Ong, Christopher J.
creator: Wang, Yuzhuo, Ph.D.
issued: 2024-07-03T18:10:12Z
issued: 2024-06-08
description: G9a, also named EHMT2, is a histone 3 lysine 9 (H3K9) methyltransferase responsible for catalyzing H3K9 mono- and dimethylation (H3K9me1 and H3K9me2). G9a contributes to various aspects of embryonic development and tissue differentiation through epigenetic regulation. Furthermore, the aberrant expression of G9a is frequently observed in various tumors, particularly in prostate cancer, where it contributes to cancer pathogenesis and progression. This review highlights the critical role of G9a in multiple cancer-related processes, such as epigenetic dysregulation, tumor suppressor gene silencing, cancer lineage plasticity, hypoxia adaption, and cancer progression. Despite the increased research on G9a in prostate cancer, there are still significant gaps, particularly in understanding its interactions within the tumor microenvironment and its broader epigenetic effects. Furthermore, this review discusses the recent advancements in G9a inhibitors, including the development of dual-target inhibitors that target G9a along with other epigenetic factors such as EZH2 and HDAC. It aims to bring together the existing knowledge, identify gaps in the current research, and suggest future directions for research and treatment strategies.
aggregated CHO: https://circle.library.ubc.ca/rest/handle/2429/88558
note: Citation: Ni, Y.; Shi, M.; Liu, L.; Lin,D.; Zeng, H.; Ong, C.; Wang, Y. G9a inCancer: Mechanisms, TherapeuticAdvancements, and ClinicalImplications. Cancers 2024, 16, 2175.https://doi.org/10.3390/cancers16122175Academic Editor: Craig N RobsonReceived: 19 April 2024Revised: 5 June 2024Accepted: 6 June 2024Published: 8 June 2024Copyright: © 2024 by the authors.Licensee MDPI, Basel, Switzerland.This article is an open access articledistributed under the terms andconditions of the Creative CommonsAttribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).cancersReviewG9a in Cancer: Mechanisms, Therapeutic Advancements, andClinical ImplicationsYuchao Ni 1,2,3, Mingchen Shi 2,3, Liangliang Liu 2,3, Dong Lin 2,3 , Hao Zeng 1,*, Christopher Ong 2,3,*and Yuzhuo Wang 2,3,41 Department of Urology, West China Hospital, Sichuan University, Chengdu 610041, China;yni@prostatecentre.com2 Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; ashi@prostatecentre.com (M.S.);lliu@prostatecentre.com (L.L.); dlin@prostatecentre.com (D.L.); ywang@bccrc.ca (Y.W.)3 Department of Urologic Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada4 Department of Experimental Therapeutics, BC Cancer, Vancouver, BC V5Z 1L3, Canada* Correspondence: kucaizeng@163.com (H.Z.); chris.ong@ubc.ca (C.O.)Simple Summary: In this review, we have summarized the crucial role of G9a in cellular biologyand disease. By synthesizing recent research discoveries, we delve into the functions of G9a ingene expression regulation, cell proliferation, and biological development. Additionally, we exploreits potential involvement in cancer and discuss its prospects as a therapeutic target specifically inprostate cancer. In summary, this review provides a comprehensive perspective on G9a, enhancesunderstanding of the significance of G9a in biology and cancer, and offers insights into future researchand drug development.Abstract: G9a, also named EHMT2, is a histone 3 lysine 9 (H3K9) methyl…
has type: Article
is shown at: 10.14288/1.0444067
language: eng
peer review status: Reviewed
provider: Vancouver : University of British Columbia Library
publisher: Multidisciplinary Digital Publishing Institute
publisher DOI: 10.3390/cancers16122175
rights: CC BY 4.0
rights URI: https://creativecommons.org/licenses/by/4.0/
scholar level: Faculty
scholar level: Researcher
subject: G9a
subject: EHMT2
subject: histone methyltransferase
subject: prostate cancer
subject: epigenetic inhibitor
type: Text
identifier URI: http://hdl.handle.net/2429/88558